The discovery of cell-free tumor and fetal DNA molecules in the plasma of cancer patients
and pregnant women, respectively, has opened up exciting opportunities in molecular …

Breast cancer (BC) is a highly heterogeneous disease. The treatment of BC is complicated
owing to intratumoral complexity. Tissue biopsy and immunohistochemistry are the current …

Detection of circulating tumor DNAs (ctDNAs) in cancer patients is an important component
of cancer precision medicine ctDNAs. Compared to the traditional physical and biochemical …

Breast cancer is the most prevalent and leading cause of mortality worldwide among
women. Cell-free DNA (cfDNA) analysis is an alternative quantitative approach to …

This paper introduces the reader to the field of liquid biopsies and cell-free nucleic acids,
focusing on circulating tumor DNA (ctDNA) in breast cancer (BC). BC is the most common …

Identifying novel circulating biomarkers predictive of response and informative about the
mechanisms of resistance, is the new challenge for breast cancer (BC) management. The …

In cancer research, the accuracy of the technology used for biomarkers detection is
remarkably important. In this context, digital PCR represents a highly sensitive and …

With dismal survival rate pancreatic cancer remains one of the most aggressive and
devastating malignancy. Predominantly, due to the absence of a dependable methodology …

Cell-free DNA (cfDNA) quantity and quality in plasma has been investigated as a non-
invasive biomarker in cancer. Previous studies have demonstrated increased cfDNA amount …

The initial discovery of cell-free DNA (cfDNA) in 1948 by Mandel and Metais has led to
numerous investigations evaluating the role of cfDNA in various disease states. cfDNA has …